APS - Diagnostics and challenges for the future

Autoimmunity Reviews

Volumn 15, Issue 11, 2016, Pages 1031-1033

  Pengo, V ^a,b   Bison, E ^a,b   Zoppellaro, G ^a,b   Padayattil Jose, S ^a,b   Denas, G ^a,b   Hoxha, A ^a,b   Ruffatti, A ^a,b   Banzato, A ^a,b  

^a Thrombosis Centre   (Italy)

^b UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

cardiolipin; inhibitor; Lupus Anticoagulant; Phospholipids; Russell Viper Venom; 2 glycoprotein 1; syndrome; Thrombosis

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; PHOSPHOLIPID ANTIBODY; BETA2 GLYCOPROTEIN 1;

ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; DIAGNOSTIC PROCEDURE; HUMAN; LABORATORY TEST; RELIABILITY; REVIEW; STANDARDIZATION; THROMBOSIS; ABORTION, SPONTANEOUS; BLOOD; COMPLICATION; IMMUNOLOGY;

ABORTION, SPONTANEOUS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; HUMANS; THROMBOSIS;

EID: 84992488160     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2016.07.028     Document Type: Review

References (39)

1. [1] Miyakis, S., Lockshin, M.D., Atsumi, M., Branch, D.W., Brey, R.L., Cervera, R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 (2006), 295–306.
2. [2] Pengo, V., Tripodi, A., Reber, G., Rand, J.H., Ortel, T.L., Galli, M., et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 7 (2009), 1737–1740.
3. [3] Devreese, K.M., de Laat, B., Mixing studies in lupus anticoagulant testing are required at least in some type of samples. J Thromb Haemost 13 (2015), 1475–1478.
4. [4] Tripodi, A., Pengo, V., More on: laboratory investigation of lupus anticoagulants: mixing studies are sometimes required. J Thromb Haemost 9 (2011), 1–2.
5. [5] Devreese, K.M., Pierangeli, S.S., de Laat, B., Tripodi, A., Atsumi, T., Ortel, T.L., Subcommittee on Lupus Anticoagulant/Phospholipid/Dependent Antibodies. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost 12 (2014), 792–795.
6. [6] Ruffatti, A., Olivieri, S., Tonello, M., Bortolati, M., Bison, E., Salvan, E., et al. Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost 6 (2008), 1693–1696.
7. [7] Danowski, A., Kickler, T.S., Petri, M., Anti-β2-glycoprotein I: prevalence, clinical correlation, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol 33 (2006), 1775–1779.
8. [8] Wisloff, F., Jacobsen, E.M., Liestol, S., Laboratory diagnosis of the antiphospholipid syndrome. Thromb Res 108 (2002), 263–271.
9. [9] Wilson, W.A., Gharavi, A.E., Koike, T., Lockshin, M.D., Branch, D.W., Piette, J.C., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42 (1999), 1309–1311.
10. [10] Pengo, V., Ruffatti, A., Del Ross, T., Tonello, M., Cuffaro, S., Hoxha, A., et al. Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile. J Thromb Haemost 11 (2013), 1–5.
11. [11] Sailer, T., Zoghlami, C., Kurz, C., Rumpold, H., Quehenberger, P., Panzer, S., et al. Anti-beta2 glycoprotein I antibodies are associated with pregnancy loss in women with the lupus anticoagulant. Thromb Haemost 95 (2006), 796–801.
12. [12] Zoghlami-Rintelen, C., Vormittag, R., Sailer, T., Lehr, S., Rumpold, H., Quehenberger, P., et al. The presence of IgG antibodies against beta2-glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant. J Thromb Haemost 3 (2005), 1160–1165.
13. [13] Pengo, V., Biasiolo, A., Pegoraro, C., Cucchini, U., Noventa, F., Iliceto, S., Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 93 (2005), 1147–1152.
14. [14] Ruffatti, A., Tonello, M., Cavazzana, A., Bagatella, P., Pengo, V., Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy. Thromb Res 123 (2009), 482–487.
15. [15] Pengo, V., Biasiolo, A., Rampazzo, P., Brocco, T., dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-beta2-glycoprotein I autoantibodies. Thromb Haemost 81 (1999), 256–258.
16. [16] Ruffatti, A., Tonello, M., Del Ross, T., et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost 96 (2006), 337–341.
17. [17] Pengo, V., Ruffatti, A., Legnani, C., et al. Clinical course of high risk patients diagnosed with antiphospholipid syndrome (APS). J Thromb Haemost 8 (2010), 237–242.
18. [18] Pengo, V., Ruffatti, A., Legnani, C., Testa, S., Fierro, T., Marongiu, F., et al. Incidence of a first thromboembolic event in asymptomatic carriers of high risk antiphospholipid antibody profile: a multicenter prospective study. Blood 118 (2011), 4714–4718.
19. [19] Bortolati, M., Marson, P., Fabris, F., Pengo, V., Facchinetti, M., De Silvestro, G., et al. Recovery from catastrophic antiphospholipid syndrome by a plasma exchange procedure: report of four cases and review of the literature. Autoimmun Rev 8 (2009 Feb), 297–301.
20. [20] Pengo, V., Banzato, A., Denas, G., Jose, S.P., Bison, E., Hoxha, A., et al. Correct laboratory approach to APS diagnosis and monitoring. Autoimmun Rev 12 (2013), 832–834.
21. [21] Pengo, V., Biasiolo, A., Gresele, P., Marongiu, F., Erba, N., Veschi, F., et al., on behalf of Participating Centres of Italian Federation of Thrombosis Centres (FCSA), Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. J Thromb Haemost 5 (2007), 925–930.
22. [22] Pengo, V., Testa, S., Martinelli, I., Ghirarduzzi, A., Legnani, C., Gresele, P., et al. Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. Thromb Res 135 (2015), 46–49.
23. [23] Girardi, G., Berman, J., Redecha, P., et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 112 (2003), 1644–1654.
24. [24] Shamonki, J.M., Salmon, J.E., Hyjek, E., Baergen, R.N., Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol, 196, 2007, 167.
25. [25] de Laat, B., Derksen, R.H., Urbanus, R.T., de Groot, P.G., IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 105 (2005), 1540–1545.
26. [26] de Laat, B., Pengo, V., Pabinger, I., Musial, J., Voskuyl, A.E., Bultink, I.E., et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 7 (2009), 1767–1773.
27. [27] Bertolaccini, M.L., Amengual, O., Andreoli, L., Atsumi, T., Chighizola, C.B., Forastiero, R., et al. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 13 (Sep 2014), 917–930.
28. [28] Pengo, V., Ruffatti, A., Tonello, M., Cuffaro, S., Banzato, A., Bison, E., et al. Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk. J Thromb Haemost 13 (2015), 782–787.
29. [29] Pengo, V., Ruffatti, A., Tonello, M., Hoxha, A., Bison, E., Denas, G., et al. Antibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles. Thromb Res 136 (2015), 161–163.
30. [30] Andreoli, L., Chighizola, C.B., Nalli, C., Gerosa, M., Borghi, M.O., Pregnolato, F., et al. Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β2 -glycoprotein I domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome. Arthritis Rheum 67 (2015), 2196–2204.
31. [31] Hoxha, A., Ruffatti, A., Mattia, E., Meneghel, L., Tonello, M., Salvan, E., et al. Relationship between antiphosphatidylserine/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome. Clin Chem Lab Med 53 (2015), 1265–1270.
32. [32] Murthy, V., Willis, R., Romay-Penabad, Z., Ruiz-Limón, P., Martínez-Martínez, L.A., Jatwani, S., et al. Value of isolated IgA anti-β2 -glycoprotein Ipositivity in the diagnosis of the antiphospholipid syndrome. Arthritis Rheum 65 (2013), 3186–3193.
33. [33] Andreoli, L., Fredi, M., Nalli, C., Piantoni, S., Reggia, R., Dall'Ara, F., et al. Clinical significance of IgA anti-cardiolipin and IgA anti-β2glycoprotein I antibodies. Curr Rheumatol Rep, 15, 2013, 343.
34. [34] Samarkos, M., Mylona, E., Kapsimali, V., The role of complement in the antiphospholipid syndrome: a novel mechanism for pregnancy morbidity. Semin Arthritis Rheum 42 (2012), 66–69.
35. [35] Agostinis, C., Durigutto, P., Sblattero, D., et al. A non–complement-fixing antibody to b2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood 123 (2014), 3478–3487.
36. [36] Endler, G., Marsik, C., Jilma, B., Schickbauer, T., Vormittag, R., Wagner, O., et al. Anti-cardiolipin antibodies and overall survival in a large cohort: preliminary report. Clin Chem 52 (2006), 1040–1044.
37. [37] Gebhart, J., Posch, F., Koder, S., Perkmann, T., Quehenberger, P., Zoghlami, C., et al. Increased mortality in patients with the lupus anticoagulant: the Vienna Lupus Anticoagulant and Thrombosis Study (LATS). Blood 125 (2015), 3477–3483.
38. [38] Sciascia, S., Sanna, G., Murru, V., Roccatello, D., Khamashta, M.A., Bertolaccini, M.L., GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxford) 52 (2013), 1397–1403.
39. [39] Zuily, S., de Laat, B., Mohamed, S., Kelchtermans, H., Shums, Z., Albesa, R., et al. Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study. Rheumatology (Oxford) 54 (2015 Nov), 2071–2075.